DataString Consulting Company Logo
DataString Consulting Company Logo
Methscopolamine Bromide Market
Home»Recent Reports»Methscopolamine Bromide Market

Methscopolamine Bromide Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802188, Published - April 2025

Segmented in Drug Class (Muscarinic Antagonist, Antispasmodic Drugs, Anticholinergic Drugs), Dosage Form (Tablets, Injection, External Preparations), Application, Distribution Channel, End-Use and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Methscopolamine Bromide Market Outlook

The market, for Methscopolamine bromide was estimated at $258.6 million in 2024; and it is anticipated to increase to $352.5 million by 2030 with projections indicating a growth to around $456.4 million by 2035. This expansion represents a compound annual growth rate (CAGR) of 5.3% over the forecast period. Such steady growth fundamentally underscores the pivotal role Methscopolamine Bromide has secured globally. Instrumental driving factors include its multifaceted uses in the pharmaceutical industry, rising demand in emerging markets, incremental healthcare reforms, and the proliferation of research and development initiatives aimed at discovering novel applications of this compound. This longevity ensures Methscopolamine Bromides ongoing relevance within the sector, bolstered by its efficacy, versatility, and steadily growing demand among end users within the pharmaceutical industry.


Methscopolamine Bromide is primarily distinguished for its extensive application as a muscarinic antagonist and in the treatment of gastrointestinal disorders. It also serves as an effective agent in ophthalmology and is increasingly being incorporated in trials for innovative, new-age medications. The major push in demand emerges from the rising prevalence of chronic gastrointestinal diseases, an aging population requiring increased care, and advanced healthcare facilities focusing on patient-centered care.


Market Size Forecast & Key Insights

2019
$258M2024
2029
$433M2034

Absolute Growth Opportunity = $175M

The Methscopolamine Bromide market is projected to grow from $258.6 million in 2024 to $433 million in 2034. This represents a CAGR of 5.3%, reflecting rising demand across Pharmaceutical Industry, Ophthalmic Solutions and Cosmetics and Personal Care.

The Methscopolamine Bromide market is set to add $175 million between 2024 and 2034, with manufacturer targeting Cosmetics & Research & Development Application projected to gain a larger market share.

With Therapeutic applications, and Technological advancements potentiating pharmacological use, Methscopolamine Bromide market to expand 68% between 2024 and 2034.

Opportunities in the Methscopolamine Bromide Market

Advancing Market Footprints Through Collaborations

Strategic partnerships and collaborations across the global medical community could significantly heighten Methscopolamine Bromides presence and impact.

Expansion in the Underevaluated Psychiatry Market and Technological Prowess in Drug Delivery Systems

Methscopolamine Bromide demonstrates potential for significant growth within the psychiatry segment, particularly in the treatment of stress-induced conditions. This niche yet rapidly growing sector remains vastly untapped and embraces novel, efficacious offerings, like Methscopolamine Bromide. Its proven ability to block certain nerve impulses in the brain that contribute to anxiety and depression could well cater to this untapped market need.

The pharmacology world is witnessing remarkable innovations in drug delivery forms. Methscopolamine Bromide, with its high bioavailability and pharmacological properties, could be ideal for integration into innovative drug delivery systems, such as transdermal patches or intranasal sprays. These advancements in drug delivery systems could augment the absorption, dispersion, and efficacy of Methscopolamine Bromide.

Growth Opportunities in North America and Europe

Europe Outlook

The Europe market for Methscopolamine Bromide is propelled by an ageing population, increasing demand for efficient and effective medicines, and burgeoning investments in healthcare. Countries like France and Germany, with their sophisticated medical facilities and established pharmaceutical sectors, predominate the market. Driven by high awareness levels and the prevalence of chronic diseases, the use of Methscopolamine Bromide has seen a surge.

North America Outlook

North America represents a significant market for Methscopolamine Bromide, with a notable increase in demand over the recent years. This upturn can be attributed to the advanced healthcare infrastructure in the region, as well as increasingly prevalent chronic conditions. Innovations in pharmaceutical technology, offering superior efficacy and improved patient compliance, have also driven significant demand, making moleculometric medicines like Methscopolamine Bromide an attractive investment for stakeholders in the healthcare sector. Enhanced awareness about the benefits and the rising prevalence of diseases like IBS and peptic ulcers have further propelled the market in North America. Amid this backdrop, competition has intensified, with pharmaceutic giants vying for market share, leading to extensive research and development activities. High growth potential is anticipated owing to the continuous advancements in the healthcare sector and the expanded use of Methscopolamine Bromide in several therapeutic applications.

North America Outlook

North America represents a significant market for Methscopolamine Bromide, with a notable increase in demand over the recent years. This upturn can be attributed to the advanced healthcare infrastructure in the region, as well as increasingly prevalent chronic conditions. Innovations in pharmaceutical technology, offering superior efficacy and improved patient compliance, have also driven significant demand, making moleculometric medicines like Methscopolamine Bromide an attractive investment for stakeholders in the healthcare sector. Enhanced awareness about the benefits and the rising prevalence of diseases like IBS and peptic ulcers have further propelled the market in North America. Amid this backdrop, competition has intensified, with pharmaceutic giants vying for market share, leading to extensive research and development activities. High growth potential is anticipated owing to the continuous advancements in the healthcare sector and the expanded use of Methscopolamine Bromide in several therapeutic applications.

Europe Outlook

The Europe market for Methscopolamine Bromide is propelled by an ageing population, increasing demand for efficient and effective medicines, and burgeoning investments in healthcare. Countries like France and Germany, with their sophisticated medical facilities and established pharmaceutical sectors, predominate the market. Driven by high awareness levels and the prevalence of chronic diseases, the use of Methscopolamine Bromide has seen a surge.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : U.S., Germany, UK, Japan, China are expected to grow at 3.4% to 5.1% CAGR

2

Emerging Markets : Indonesia, Brazil, South Africa are expected to grow at 6.1% to 7.3% CAGR

Market Analysis Chart

As we delve deeper into the dynamics of the Methscopolamine Bromide market, we appreciate that its landscape is not only without obstacles nor free of propellers. A primary market driver is Methscopolamine Bromides extensive medical applications. Leveraging its potent anticholinergic properties, it is notably utilized for gastrointestinal disorders treatment, making its market value substantial within the healthcare industry. Furthermore, its use in producing effective pre-anesthetic medication considerably propels its demand, particularly within surgical procedures.

Recent Developments and Technological Advancement

December 2024

Endo Pharmaceuticals announced the launch of an innovative Methscopolamine Bromide inhaler, designed to increase patient comfort and efficiency in drug administration, solidifying its position as a leader in the market.

October 2024

Zydus Cadila received FDA approval for its Methscopolamine Bromide transdermal patches offering a non-invasive treatment option for patients battling irritable bowel syndrome, driving the market towards value-based care.

July 2024

AstraZeneca initiated phase III clinical trials for a new variant of Methscopolamine Bromide aimed at treating peptic ulcers, potentially expanding the drugs application and redefining its market dynamics.

Methscopolamine Bromide, a potent anticholinergic drug, has seen significant developments in the recent market landscape. As an essential component in the treatment of peptic ulcers, its demand continues to rise in parallel with the increasing prevalence of such ailments.

Impact of Industry Transitions on the Methscopolamine Bromide Market

As a core segment of the Pharmaceutical industry, the Methscopolamine Bromide market develops in line with broader industry shifts. Over recent years, transitions such as Embracing Technological Advancements and Increasing Demand for Peptic Ulcer Disease Treatment have redefined priorities across the Pharmaceutical sector, influencing how the Methscopolamine Bromide market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Embracing Technological Advancements:

The pharmaceutical sector has historically been slow to adapt to change, but with the ubiquity of digital technology, this is rapidly altering. Notably, this shift can be seen in the manufacturing processes of Methscopolamine Bromide, an element extensively used in the treatment of peptic ulcer disease and irritable bowel syndrome. New technological developments such as continuous manufacturing and AI have optimized the production cycle, hence increasing efficiency and reducing the manufacturing cost. These transitions have made advancements in precision and personalized medication possible, leading to improved patient outcomes.

2

Increasing Demand for Peptic Ulcer Disease Treatment:

Increased stress levels and unhealthy eating habits have led to a surge in the prevalence of peptic ulcer disease globally. This trend directly impacts the demand for Methscopolamine Bromide, leading to significant expansion in its market size. The onus of catering to increased demand challenges manufacturers to innovate with their manufacturing processes and supply chain strategies, calling for a paradigm shift in the industry.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Methscopolamine Bromide market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Therapeutic Applications, and Increasing R&D Investments

Methscopolamine Bromide is also a proven lifesaver in multiple therapeutic domains, especially in gastroenterology, cardiology and ophthalmology. As the global disease burden in these fields continues to rise, there is also an escalating demand for reliable therapeutics such as Methscopolamine Bromide. The drugs ability to effectively control various functions of the parasympathetic nervous system positions it as a crucial player in managing diverse health conditions.
Rapid scientific progression pushes the growth of R&D investments in the pharmaceutical industry. This increased expenditure skews towards the exploration and understanding of existing drugs, including Methscopolamine Bromide, to leverage their full potential.
Technological advancements in pharmaceutical practices have also allowed for the optimized use of Methscopolamine Bromide. The trend of precision medicine allows for targeted therapies, in which Methscopolamine Bromide can also play a significant role, given its diverse scope of action on the nervous system. This innovation not only supports health outcomes, but also strategically places Methscopolamine Bromide at the center of prolific pharmacological also advances.

Restraint: Stringent Regulatory Compliance

Getting approval for the sale and distribution of Methscopolamine Bromide is a daunting task due to its stringent regulatory compliance requirements. Authorities such as the FDA demand rigorous tests and trials to ascertain the drugs safety and efficacy. These processes can be time-consuming and expensive, posing major challenges for manufacturers, and may stifle new entrants into the market. This potentially reduces market competition and hampers the growth and accessibility of Methscopolamine Bromide.

Challenge: Side Effects and Health Risks

Methscopolamine Bromide has associated side effects and health risks. Although its a potent medication for alleviating conditions like peptic ulcers and IBS , it can cause adverse reactions like dry mouth, blurred vision, and difficulty in urination. Patients apprehension towards these side effects can deter the demand for Methscopolamine Bromide.

Supply Chain Landscape

Raw Material Suppliers

Sigma-Aldrich

Thermo Fisher Scientific

API Manufacturers

Glenmark Pharmaceuticals

Mylan Laboratories

Drug Formulation Manufacturers
Teva Pharmaceuticals / Astrazeneca
End-User Industry
Pharmaceutical / Research laboratories
Raw Material Suppliers

Sigma-Aldrich

Thermo Fisher Scientific

API Manufacturers

Glenmark Pharmaceuticals

Mylan Laboratories

Drug Formulation Manufacturers

Teva Pharmaceuticals

Astrazeneca

End-User Industry

Pharmaceutical

Research laboratories

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Gastrointestinal Treatments
Healthcare and Pharmaceuticals
Pfizer Inc.
Development and distribution of high-quality Methscopolamine Bromide drugs for effective gastrointestinal relief
Ophthalmology
Healthcare and Pharmaceuticals
Novartis AG
Production of effective Methscopolamine Bromide eye drops for pre-operative and post-operative care
Respiratory Care
Healthcare and Pharmaceuticals
GlaxoSmithKline plc
Incorporation of Methscopolamine Bromide into respiratory medication for COPD treatment
Antispasmodic Therapy
Healthcare and Pharmaceuticals
Sanofi
Designing Methscopolamine Bromide-based antispasmodic drugs for conditions such as IBS

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Methscopolamine Bromide market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Methscopolamine Bromide in Ophthalmic Solutions, Cosmetics and Personal Care and Pharmaceutical Industry

Ophthalmic Solutions

This compound is incorporated in ophthalmic solutions as well, working as a cycloplegic and mydriatic agent for dilating the pupil during diagnostic procedures and surgeries. Renowned companies like Novartis and Allergan utilize Methscopolamine Bromide in their range of ophthalmic solutions, leading the market through innovation and efficacy.

Cosmetics and Personal Care

Methscopolamine Bromide also finds its place in the cosmetics and personal care industry where its used in several skincare products due to its unique property to reduce sweat. Hence, this compound is widely used in antiperspirant products. The top players that leverage this application include GlaxoSmithKline and Procter & Gamble, recognized for their wide variety of personal care products utilizing Methscopolamine Bromide.

Pharmaceutical Industry

Methscopolamine Bromide is primarily used in the pharmaceutical industry as an antispasmodic agent. It blockades the transmission at parasympathetic sites in smooth muscle, secretory glands, and the CNS, providing benefit in the treatment of conditions such as peptic ulcers and IBS . Major players in this application include King Pharmaceuticals and Pfizer, known for their cutting-edge research and development capabilities to utilize Methscopolamine Bromide effectively.

Methscopolamine Bromide vs. Substitutes:
Performance and Positioning Analysis

Methscopolamine Bromide stands out amid counterparts with its exceptional anticholinergic properties, aiding in reducing stomach secretions, while alternatives may not be as specific. Its unique market positioning lies in its potential growth within the medical industry

Methscopolamine Bromide
  • Scopolamine /
  • Atropine /
  • Hyoscyamine
    Effective for relief of peptic ulcers, Reduces excessive salivation and secretion
    Can cause dizziness and dry mouth, Potentially harmful for people with glaucoma
    Higher effectiveness, broad therapeutic applications
    Potential side effects, high cost

Methscopolamine Bromide vs. Substitutes:
Performance and Positioning Analysis

Methscopolamine Bromide

  • Effective for relief of peptic ulcers, Reduces excessive salivation and secretion
  • Can cause dizziness and dry mouth, Potentially harmful for people with glaucoma

Scopolamine / Atropine / Hyoscyamine

  • Higher effectiveness, broad therapeutic applications
  • Potential side effects, high cost

Methscopolamine Bromide stands out amid counterparts with its exceptional anticholinergic properties, aiding in reducing stomach secretions, while alternatives may not be as specific. Its unique market positioning lies in its potential growth within the medical industry

Loading...

Research Methodology

This market research methodology defines the Methscopolamine Bromide market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Methscopolamine Bromide across Pharmaceuticals, Cosmetics, and Research & Development Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Johnson & Johnson, Mallinckrodt Pharmaceuticals, and Mylan Pharmaceuticals Inc. by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Suppliers, API Manufacturers, and Drug Formulation Manufacturers. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Methscopolamine Bromide segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Suppliers (Sigma-Aldrich, Thermo Fisher Scientific), API Manufacturers (Glenmark Pharmaceuticals, Mylan Laboratories), and Drug Formulation Manufacturers. Our parallel substitute analysis examines Scopolamine, Atropine, and Hyoscyamine, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Johnson & Johnson, Mallinckrodt Pharmaceuticals, and Mylan Pharmaceuticals Inc., analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Methscopolamine Bromide market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Methscopolamine Bromide Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 272 million
Revenue Forecast in 2034USD 433 million
Growth RateCAGR of 5.3% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024258 million
Growth OpportunityUSD 175 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024258 million USD
Market Size 2027301 million USD
Market Size 2029334 million USD
Market Size 2030352 million USD
Market Size 2034433 million USD
Market Size 2035456 million USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredDrug Class, Dosage Form, Application, Distribution Channel, End-Use
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledJohnson & Johnson, Mallinckrodt Pharmaceuticals, Mylan Pharmaceuticals Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Watson Pharmaceuticals Inc., GlaxoSmithKline Plc., Boehringer Ingelheim GmbH, Shire plc, Allergan Inc. and AstraZeneca Plc.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Methscopolamine Bromide Market Size, Opportunities & Strategic Insights, by Drug Class

4.1Muscarinic Antagonist
4.2Antispasmodic Drugs
4.3Anticholinergic Drugs
Chapter 5

Methscopolamine Bromide Market Size, Opportunities & Strategic Insights, by Dosage Form

5.1Tablets
5.2Injection
5.3External Preparations
Chapter 6

Methscopolamine Bromide Market Size, Opportunities & Strategic Insights, by Application

6.1Pharmaceuticals
6.2Cosmetics
6.3Research & Development
6.4Others
Chapter 7

Methscopolamine Bromide Market Size, Opportunities & Strategic Insights, by Distribution Channel

7.1Online Pharmacies
7.2Retail Pharmacies
7.3Hospital Pharmacies
Chapter 8

Methscopolamine Bromide Market Size, Opportunities & Strategic Insights, by End-Use

8.1Hospitals
8.2Homecare
8.3Specialty Clinics
8.4Others
Chapter 9

Methscopolamine Bromide Market, by Region

9.1North America Methscopolamine Bromide Market Size, Opportunities, Key Trends & Strategic Insights
9.1.1U.S.
9.1.2Canada
9.2Europe Methscopolamine Bromide Market Size, Opportunities, Key Trends & Strategic Insights
9.2.1Germany
9.2.2France
9.2.3UK
9.2.4Italy
9.2.5The Netherlands
9.2.6Rest of EU
9.3Asia Pacific Methscopolamine Bromide Market Size, Opportunities, Key Trends & Strategic Insights
9.3.1China
9.3.2Japan
9.3.3South Korea
9.3.4India
9.3.5Australia
9.3.6Thailand
9.3.7Rest of APAC
9.4Middle East & Africa Methscopolamine Bromide Market Size, Opportunities, Key Trends & Strategic Insights
9.4.1Saudi Arabia
9.4.2United Arab Emirates
9.4.3South Africa
9.4.4Rest of MEA
9.5Latin America Methscopolamine Bromide Market Size, Opportunities, Key Trends & Strategic Insights
9.5.1Brazil
9.5.2Mexico
9.5.3Rest of LA
9.6CIS Methscopolamine Bromide Market Size, Opportunities, Key Trends & Strategic Insights
9.6.1Russia
9.6.2Rest of CIS
Chapter 10

Competitive Landscape

10.1Competitive Dashboard & Market Share Analysis
10.2Company Profiles (Overview, Financials, Developments, SWOT)
10.2.1Johnson & Johnson
10.2.2Mallinckrodt Pharmaceuticals
10.2.3Mylan Pharmaceuticals Inc.
10.2.4Pfizer Inc.
10.2.5Novartis AG
10.2.6Teva Pharmaceutical Industries Ltd.
10.2.7Watson Pharmaceuticals Inc.
10.2.8GlaxoSmithKline Plc.
10.2.9Boehringer Ingelheim GmbH
10.2.10Shire plc
10.2.11Allergan Inc.
10.2.12AstraZeneca Plc.